Cantor Fitzgerald Expects Weaker Earnings for Arcellx

Arcellx, Inc. (NASDAQ:ACLX) – Stock analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of Arcellx in a note issued to investors on Thursday, October 9th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings of ($3.72) per share for the year, down from their prior forecast of ($2.98). Cantor Fitzgerald currently has a “Hold” rating and a $88.00 price target on the stock. The consensus estimate for Arcellx’s current full-year earnings is ($1.58) per share. Cantor Fitzgerald also issued estimates for Arcellx’s FY2026 earnings at ($3.56) EPS.

Arcellx (NASDAQ:ACLX) last issued its earnings results on Thursday, August 7th. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.09. The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $16.76 million. Arcellx had a negative net margin of 329.93% and a negative return on equity of 43.04%.

Other equities research analysts have also issued reports about the company. Scotiabank boosted their target price on Arcellx from $93.00 to $133.00 and gave the stock a “sector outperform” rating in a research report on Thursday, July 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Arcellx in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $115.00 price objective on shares of Arcellx in a research note on Monday, June 16th. Finally, Citigroup began coverage on shares of Arcellx in a report on Tuesday, June 17th. They issued a “buy” rating and a $110.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Arcellx has a consensus rating of “Moderate Buy” and a consensus price target of $112.69.

Arcellx Stock Performance

Shares of NASDAQ:ACLX opened at $86.23 on Monday. The company has a market capitalization of $4.78 billion, a PE ratio of -25.21 and a beta of 0.31. The stock has a fifty day moving average of $75.70 and a 200-day moving average of $68.13. Arcellx has a one year low of $47.86 and a one year high of $107.37.

Insider Activity

In other Arcellx news, insider Christopher Heery sold 21,034 shares of Arcellx stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $81.28, for a total transaction of $1,709,643.52. Following the completion of the sale, the insider owned 624 shares of the company’s stock, valued at $50,718.72. This trade represents a 97.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 37,146 shares of company stock worth $3,000,136. Company insiders own 8.35% of the company’s stock.

Institutional Trading of Arcellx

Institutional investors have recently bought and sold shares of the company. State of Wyoming acquired a new position in Arcellx in the 2nd quarter worth about $28,000. GAMMA Investing LLC lifted its holdings in shares of Arcellx by 104.1% during the 1st quarter. GAMMA Investing LLC now owns 494 shares of the company’s stock valued at $32,000 after buying an additional 252 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock valued at $49,000 after buying an additional 486 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Arcellx in the first quarter worth approximately $50,000. Finally, GF Fund Management CO. LTD. increased its holdings in Arcellx by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 1,384 shares of the company’s stock worth $91,000 after buying an additional 249 shares during the last quarter. Institutional investors and hedge funds own 96.03% of the company’s stock.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).